title: [Combined chemohormonal therapy for metastatic hormone-sensitive prostate cancer : Effectiveness and update as a joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
authors.affiliation: Klinik für Urologie und Kinderurologie, Universität des Saarlandes, Kirrbergerstraße, 66421, Homburg/Saar, Deutschland. carsten.ohlmann@uks.eu.
authors.forename: C-H
authors.initials: CH
authors.lastname: Ohlmann
authors.affiliation: Klinik für Urologie, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Gschwend
authors.affiliation: Klinik für Urologie, Charité-Universitätsmedizin Berlin, Berlin, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Miller
mesh_terms: D000726:Androgen Antagonists / Q000592:standards / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000592:standards; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary*; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014572:Urology / Q000592:standards
chemical_list: D000726:Androgen Antagonists